{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:19:59Z","timestamp":1782159599893,"version":"3.54.5"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapies engage the individual\u2019s immune system to fight both hematologic and solid malignancies and have led to durable clinical responses for many patients. A subset of immunotherapies, including T cell engagers (TCEs) and chimeric antigen receptor T-cell therapies (CAR-T), use T cell mediated mechanisms to induce cancer cell death. These therapies can be very effective against the cancer while also causing significant systemic and neurologic toxicity, including cognitive dysfunction. Here, we provide a review on the existing and emerging literature describing the acute, subacute, and potential long-term effects of CAR-T cells and other T-cell-engaging therapies on cognition. While the acute effects on cognition, including immune effector cell-associated neurotoxicity syndrome are becoming better characterized, there is mixed data on the long-term subjective and objective cognitive outcomes after T-cell-based immunotherapies. Further research is needed, especially as these promising and effective therapies become more commonly used for both hematologic and solid malignancies.<\/jats:p>","DOI":"10.1093\/noajnl\/vdag021","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:58:22Z","timestamp":1773932302000},"page":"13-24","source":"Crossref","is-referenced-by-count":1,"title":["Cognitive dysfunction associated with cellular immunotherapy for cancer"],"prefix":"10.1093","volume":"8","author":[{"given":"Anna G","family":"Hauswirth","sequence":"first","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-9564","authenticated-orcid":false,"given":"Michael W","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0136","authenticated-orcid":false,"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026062204515661700_vdag021-B1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/S41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2026062204515661700_vdag021-B2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/J.JTCT.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/S41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2026062204515661700_vdag021-B4","doi-asserted-by":"publisher","first-page":"102991","DOI":"10.1016\/j.ctrv.2025.102991","article-title":"T-cell engager toxicity in clinical phase trials; a systematic review and meta-analysis","volume":"139","author":"Za\u00efr","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026062204515661700_vdag021-B5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient perspectives on health-related quality of life in diffuse large B-Cell lymphoma treated with car T-Cell therapy: a qualitative study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol Ther"},{"key":"2026062204515661700_vdag021-B6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/BLOODADVANCES.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"key":"2026062204515661700_vdag021-B7","doi-asserted-by":"publisher","first-page":"103126","DOI":"10.1016\/J.JAUT.2023.103126","article-title":"Cognition following chimeric antigen receptor T-cell therapy: a systematic review","volume":"140","author":"Kazzi","year":"2023","journal-title":"J Autoimmun"},{"key":"2026062204515661700_vdag021-B8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2013BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026062204515661700_vdag021-B9","doi-asserted-by":"publisher","first-page":"1551424","DOI":"10.3389\/FIMMU.2025.1551424\/XML","article-title":"Engaging T cells for cleanup","volume":"16","author":"Mungalov","year":"2025","journal-title":"Front Immunol"},{"key":"2026062204515661700_vdag021-B10","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1535-7163.MCT-20-0508","article-title":"Preclinical assessment of AMG 596, a bispecific T-cell engager (BiTE) immunotherapy targeting the tumor-specific antigen EGFRvIII","volume":"20","author":"Sternjak","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026062204515661700_vdag021-B16","doi-asserted-by":"publisher","first-page":"TPS2071","DOI":"10.1200\/JCO.2019.37.15_SUPPL.TPS2071","article-title":"Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease","volume":"37","author":"Rosenthal","year":"2019","journal-title":"JCO"},{"key":"2026062204515661700_vdag021-B17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMC2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/S41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"2026062204515661700_vdag021-B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMRA1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B20","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/FIMMU.2023.1303935","article-title":"Lymphodepletion\u2013an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"2026062204515661700_vdag021-B21","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/BLOOD-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMOA1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B23","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMOA1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. The.","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2026062204515661700_vdag021-B26","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMOA1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B27","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/S41591-024-02893-Z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"2026062204515661700_vdag021-B28","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMOA2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMOA2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease\u2013a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/S41422-025-01128-1;TECHMETA","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"issue":"3","key":"2026062204515661700_vdag021-B31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.31887\/DCNS.2019.21.3\/PHARVEY","article-title":"Domains of cognition and their assessment","volume":"21","author":"Harvey","year":"2019","journal-title":"Dialogues Clin Neurosci"},{"key":"2026062204515661700_vdag021-B32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/NRNEUROL.2014.181","article-title":"Classifying neurocognitive disorders: the DSM-5 approach","volume":"10","author":"Sachdev","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"2026062204515661700_vdag021-B33","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.18.02363","article-title":"Why are objective and perceived cognitive function weakly correlated in patients with cancer?","volume":"37","author":"Costa","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026062204515661700_vdag021-B34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/J.JGO.2018.08.003","article-title":"Prospective comparison of the montreal cognitive assessment (MoCA) and the mini mental state examination (MMSE) in geriatric oncology","volume":"10","author":"Rambeau","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2026062204515661700_vdag021-B35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/J.BBMT.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026062204515661700_vdag021-B36","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/S11136-014-0732-6","article-title":"Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment","volume":"23","author":"Cella","year":"2014","journal-title":"Qual Life Res"},{"issue":"7","key":"2026062204515661700_vdag021-B37","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/ARCLIN\/ACAA128","article-title":"Normative reference values, reliability, and Item-level symptom endorsement for the PROMIS\u00ae v2.0 cognitive Function-Short forms 4a, 6a and 8a","volume":"36","author":"Iverson","year":"2021","journal-title":"Arch Clin Neuropsychol"},{"key":"2026062204515661700_vdag021-B38","author":"Ansbaugh","year":"2025"},{"key":"2026062204515661700_vdag021-B39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.6004\/JNCCN.2025.0028","article-title":"NCCN guidelines\u00ae insights: Survivorship, version 2.2025: featured updates to the NCCN guidelines\u00ae","volume":"23","author":"Sanft","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026062204515661700_vdag021-B40","author":"iPAAC","year":"2021"},{"key":"2026062204515661700_vdag021-B41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","article-title":"International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer","volume":"12","author":"Wefel","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026062204515661700_vdag021-B42","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/BLOOD.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026062204515661700_vdag021-B43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med"},{"key":"2026062204515661700_vdag021-B44","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/BLOOD-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B45","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"2026062204515661700_vdag021-B46","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/BLOOD.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1212\/WNL.0000000000005910","article-title":"EEG findings in CAR T-cell therapy-related encephalopathy","volume":"91","author":"Herlopian","year":"2018","journal-title":"Neurology"},{"key":"2026062204515661700_vdag021-B48","doi-asserted-by":"publisher","first-page":"e200111","DOI":"10.1212\/NXI.0000000000200111","article-title":"Frontal intermittent rhythmic Delta activity is a useful diagnostic tool of neurotoxicity after CAR T-Cell infusion","volume":"10","author":"Huby","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026062204515661700_vdag021-B49","doi-asserted-by":"publisher","first-page":"e200488","DOI":"10.1212\/CPJ.0000000000200488","article-title":"Neuroimaging findings of CAR T-cell-\u00adassociated neurotoxicity: a review","volume":"15","author":"Vichare","year":"2025","journal-title":"Neurol Clin Pract"},{"key":"2026062204515661700_vdag021-B50","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/BRAIN\/AWZ053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"2026062204515661700_vdag021-B51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/S41591-023-02276-W","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"2026062204515661700_vdag021-B52","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/S41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"2026062204515661700_vdag021-B53","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026062204515661700_vdag021-B54","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/NEUONC\/NOAC034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026062204515661700_vdag021-B55","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2026062204515661700_vdag021-B56","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1182\/BLOOD.2025028964","article-title":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy","volume":"146","author":"Kaulen","year":"2025","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B57","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/JAMANEUROL.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-Cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026062204515661700_vdag021-B58","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/BLOODADVANCES.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"2026062204515661700_vdag021-B59","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2217\/IMT-2020-0161","article-title":"Neurological adverse events following CAR T-Cell therapy: a Real-World analysis","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"key":"2026062204515661700_vdag021-B60","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/NEUONC\/NOAD118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026062204515661700_vdag021-B61","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/BLOODADVANCES.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"2026062204515661700_vdag021-B62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/J.CLLC.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"2026062204515661700_vdag021-B63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/S41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026062204515661700_vdag021-B64","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/BLOOD.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B65","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jamaneurol.2024.2506","article-title":"Parkinsonism following chimeric antigen receptor T cell therapy","volume":"81","author":"Gudera","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026062204515661700_vdag021-B66","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"2026062204515661700_vdag021-B67","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026062204515661700_vdag021-B68","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/BLOOD-2023-182695","article-title":"Adverse effects and non-relapse mortality of BCMA-directed immunotherapies\u202f: an FDA adverse event reporting system (FAERS) database study","volume":"142","author":"Gong","year":"2023","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062204515661700_vdag021-B70","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-050817-084903","article-title":"Cognitive effects of cancer and cancer treatments","volume":"14","author":"Ahles","year":"2018","journal-title":"Annu Rev Clin Psychol"},{"key":"2026062204515661700_vdag021-B71","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/CNCR.27854","article-title":"Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials","volume":"119","author":"Hui","year":"2013","journal-title":"Cancer"},{"key":"2026062204515661700_vdag021-B72","doi-asserted-by":"publisher","first-page":"236.e1","DOI":"10.1016\/j.jtct.2025.01.886","article-title":"Long-term cognitive outcomes in adult patients receiving chimeric antigen receptor T-Cell therapies","volume":"31","author":"Barata","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B73","doi-asserted-by":"publisher","first-page":"305.e1-305","DOI":"10.1016\/j.jtct.2022.03.023","article-title":"Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B74","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1212\/WNL.0000000000201083","article-title":"Long-term neurologic safety in patients with B-Cell lymphoma treated with anti-CD19 chimeric antigen receptor T-Cell therapy","volume":"99","author":"Ursu","year":"2022","journal-title":"Neurology"},{"key":"2026062204515661700_vdag021-B75","doi-asserted-by":"publisher","first-page":"254.e1-254","DOI":"10.1016\/J.JTCT.2023.01.004","article-title":"Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T","volume":"29","author":"Akinola","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B76","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1002\/HEM3.72","article-title":"Remission after CAR T-cell therapy: do lymphoma patients recover a normal life?","volume":"8","author":"Perthus","year":"2024","journal-title":"Hemasphere"},{"key":"2026062204515661700_vdag021-B77","doi-asserted-by":"publisher","first-page":"401.e1-401","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in patients\u2019 perceived cognition following chimeric antigen receptor T-Cell therapy for lymphoma","volume":"28","author":"Barata","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026062204515661700_vdag021-B79","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/J.JTCT.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B80","doi-asserted-by":"publisher","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-Reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026062204515661700_vdag021-B81","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1101\/2024.05.14.594163","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"bioRxiv"},{"key":"2026062204515661700_vdag021-B82","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/J.CRITREVONC.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2026062204515661700_vdag021-B83","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"2026062204515661700_vdag021-B84","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09540261.2013.864260","article-title":"Prevalence, mechanisms, and management of cancer-related cognitive impairment","volume":"26","author":"Janelsins","year":"2014","journal-title":"Int Rev Psychiatry"},{"key":"2026062204515661700_vdag021-B85","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2020.11.021","article-title":"Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: an unexpected case of fludarabine-associated progressive leukoencephalopathy","volume":"144","author":"Winter","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026062204515661700_vdag021-B86","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026062204515661700_vdag021-B87","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026062204515661700_vdag021-B88","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/BLOODADVANCES.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"2026062204515661700_vdag021-B89","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/BLOODADVANCES.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy\u2013related CRS and ICANS: a multicenter retrospective \u00adanalysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv"},{"key":"2026062204515661700_vdag021-B90","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/BLOOD.2024028172","article-title":"Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment","volume":"145","author":"Blumenberg","year":"2025","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B91","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1182\/BLOODADVANCES.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv"},{"key":"2026062204515661700_vdag021-B92","doi-asserted-by":"publisher","first-page":"eadj6251","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"2026062204515661700_vdag021-B93","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/13803395.2025.2523368","article-title":"Neuropsychological functioning in non-CNS cancer patients","volume":"47","author":"Sleurs","year":"2025","journal-title":"J Clin Exp Neuropsychol"},{"key":"2026062204515661700_vdag021-B94","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/BLOOD-2021-150431","article-title":"A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"2026062204515661700_vdag021-B95","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/BJH.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag021\/67415896\/vdag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/Supplement_5\/13\/67415896\/vdag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/Supplement_5\/13\/67415896\/vdag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:52:12Z","timestamp":1782118332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/8\/Supplement_5\/13\/8529037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":95,"journal-issue":{"issue":"Supplement_5","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag021","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,19]]}}}